Paper658097
Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents.
Barlogie B and 1 other. Eur J Cancer (1965), 1978. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents. Papers, record 658097. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/658097
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cell Cycle | Major topic |
| Cells, Cultured | |
| Depression, Chemical | |
| Humans | |
| Lymphoma | |
| Time Factors |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 21033700 | A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells. | Biochemistry | 2010 | https://conductscience.org/library/papers/21033700 | PubMed |
| 12201486 | Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12201486 | PubMed |
| 10857993 | Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. | Invest New Drugs | 2000 | https://conductscience.org/library/papers/10857993 | PubMed |
| 9743293 | Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9743293 | PubMed |
| 7340985 | A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7340985 | PubMed |
| 7031350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
| 6684118 | Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. | J Cancer Res Clin Oncol | 1983 | https://conductscience.org/library/papers/6684118 | PubMed |
| 6196896 | Flow-cytophotometric studies on urine sediments of patients treated with anti-cancer-drugs. | Urol Res | 1983 | https://conductscience.org/library/papers/6196896 | PubMed |
| 3297462 | The clinical pharmacology of etoposide and teniposide. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3297462 | PubMed |
| 1624543 | Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity. | J Cancer Res Clin Oncol | 1992 | https://conductscience.org/library/papers/1624543 | PubMed |
| 1333370 | Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine. | Cancer Chemother Pharmacol | 1992 | https://conductscience.org/library/papers/1333370 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/658097
GET https://conductscience.org/api/papers/v1/658097/authors